Form 4: Enliven Therapeutics CMO Executes Stock Option Plan

Chief Medical Officer Helen Louise Collins exercised options and sold 5,000 shares of Enliven Therapeutics common stock.

Summary

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, exercised options for 5,000 shares at a strike price of $2.48.
• The shares were subsequently sold in three tranches at weighted average prices of $45.8107, $47.3896, and $48.0555.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 19, 2025.
• Following these transactions, the reporting person retains beneficial ownership of 25,000 shares and 131,268 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned divestment by an executive that does not signal a change in company fundamentals.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to liquidity rather than reactive selling.
• The exercise price of $2.48 compared to the sale prices in the $45-$48 range reflects significant value appreciation for the executive.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Future sales by insiders under 10b5-1 plans may continue to reduce executive ownership levels.
• Market perception of insider selling can occasionally lead to short-term volatility in share price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice in the biotechnology sector, allowing executives to diversify their holdings while avoiding concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity compensation in publicly traded biotech firms.
• The volume of shares sold is relatively small compared to the total holdings of the executive, which is consistent with typical executive wealth management strategies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for additional insider activity.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Insider Trading, Form 4, Biotech, Executive Compensation